SBH
CDNA icon

Segall Bryant & Hamill’s CareDx CDNA Stock Holding History

Segall Bryant & Hamill’s Portfolio CDNA Stock Details CDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-67,317
Closed -$1.14M – 713
2022
Q3 		$1.14M Buy
67,317
+5,769
+9% +$124K 0.01% 483
2022
Q2 		$1.32M Buy
+61,548
New +$1.71M 0.01% 469

Other funds holding CDNA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Segall Bryant & Hamill's CDNA Position: Q4 2022 in Review

Segall Bryant & Hamill sold out of CareDx (CDNA) in Q4 2022, closing a stake of 67,317 shares — an estimated $1.14M sold.

Segall Bryant & Hamill first reported a position in CDNA in Q2 2022 and held it in 2 quarters. The position peaked at $1.32M in Q2 2022. 168 funds tracked by Wall St. Rank hold CDNA as of Q4 2022.

  • Segall Bryant & Hamill reported no remaining CareDx position as of Q4 2022 after selling out during the quarter.
  • Segall Bryant & Hamill sold 67,317 CareDx shares in Q4 2022, an estimated $1.14M.
  • Segall Bryant & Hamill first reported a position in CareDx in Q2 2022 and held it in 2 quarters.
  • Segall Bryant & Hamill's CareDx position peaked at $1.32M in Q2 2022.
  • 168 funds tracked by Wall St. Rank held CareDx as of Q4 2022.

Based on Segall Bryant & Hamill's 13F filing for Q4 2022, filed 14 Feb 2023.